Stockscreener 앱 받기
1.84
0.54%
-0.02
전일 마감가:
$1.86
열려 있는:
$1.85
하루 거래량:
254.58K
Relative Volume:
1.00
시가총액:
$96.57M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.3431
EPS:
-1.37
순현금흐름:
$-46.54M
1주 성능:
+2.21%
1개월 성능:
+25.85%
6개월 성능:
+7.56%
1년 성능:
-28.29%
1일 변동 폭
$1.80
$1.8828
1주일 범위
$1.68
$1.905
52주 변동 폭
$1.12
$3.52
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MIST | 1.845 | 96.57M | 0 | -59.69M | -46.54M | -1.37 |
| VRTX | 450.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.99 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.45 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - MSN
Seres Therapeutics Q3 2024 Earnings Preview - MSN
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
Milestone Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Gyre Therapeutics Revenue Falls 20% as Phase 3 Trial Milestone Nears Critical Data | GYRE Stock News - StockTitan
Milestone Pharmaceuticals Inc. (MIST) Quarterly 10-Q Report - Quartz
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharma Trims Losses 38% as CARDAMYST Shows Strong Phase 3 Results in China | MIST Stock News - StockTitan
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
Armata Pharmaceuticals Hits Key Milestone in Bacteriophage Therapy Trial, Eyes 2025 Data | ARMP Stock News - StockTitan
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - Simply Wall St
Head to Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Alkermes (NASDAQ:ALKS) - Defense World
InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Creso Pharma Limited Exceeds Milestone of 3 Million Anibidiol® Doses Sold in Europe - Marketscreener.com
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies - Marketscreener.com
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Yahoo Finance
MSD acquires cancer therapeutics developer Modifi Biosciences - Pharmaceutical Technology
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - BioSpace
Biotech stock tumbles after unexplained 1,446% gain - MSN
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Wainwright maintains Buy rating on Milestone Pharma stock By Investing.com - Investing.com UK
Millennium Management LLC Sells 105,682 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46% - Yahoo Finance
IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults - Yahoo Finance
OKUR stock soars to all-time high, reaching $20 milestone - Investing.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MyChesCo
1 AI Biotech Stock That Just Scored a Major Milestone - TradingView
1 AI Biotech Stock That Just Scored A Major Milestone - Barchart
Antiarrhythmic Drugs Market Size And Share Report, 2030 - Grand View Research
Candel therapeutics insider sells shares worth over $240k - Investing.com
Scientech Research LLC Invests $289,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Susquehanna Fundamental Investments LLC Makes New Investment in Boston Scientific Co. (NYSE:BSX) - Defense World
MP Materials (NYSE:MP) PT Raised to $23.00 - Defense World
ProShare Advisors LLC Raises Stock Holdings in Bruker Co. (NASDAQ:BRKR) - Defense World
Toronto Dominion Bank Has $2.66 Million Position in Veeva Systems Inc. (NYSE:VEEV) - Defense World
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Increase in Short Interest - MarketBeat
NRX-100 (Ketamine) Reaches Stability Milestone - Contract Pharma
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - StockTitan
Milestone Pharmaceuticals to Host Investor KOL Event - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 0.7% - MarketBeat
Delaware Court of Chancery Finds Buyer Failed to Use Commercially Reasonable Efforts in Pharma Milestone Payment Case - The Harvard Law School Forum on Corporate Governance
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - StockTitan
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical - BioSpace
Scilex Holding (NASDAQ:SCLX) Stock Quotes, Forecast and News Summary - Benzinga
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):